Ketamine on the Edge: Mindbloom’s At-Home Injections Spark Debate; UK Eyes Tougher Laws; DEA to Regulate Telehealth Prescribing; Spravato Sales Top $1bn

Words by Josh Hardman.

We have barely kicked off 2025 and already a handful of ketamine-related news stories have emerged. In this ketamine-focused round-up, we explore:

• The British government is considering reclassifying ketamine to Class A, alongside drugs like cocaine and heroin, ostensibly due to rising illicit use and health concerns.
• Janssen’s esketamine nasal spray, Spravato, has become a blockbuster drug with over $1 billion in annual sales and now FDA approval as a monotherapy for treatment-resistant depression. But a recent meta-analysis questions its efficacy, particularly in addressing suicidality.
• Deep Dive: Mindbloom’s new at-home injectable ketamine program has sparked significant controversy within the psychedelics community, with critics raising safety, ethical, and regulatory concerns—while the company dismisses the backlash as industry-driven opposition and doubles down on its marketing efforts.
• DEA publishes its proposed telehealth registration scheme for entities looking to prescribe controlled substances remotely, which will have repercussions for at-home ketamine providers...